Medindia

X

Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook

Saturday, February 9, 2008 General News J E 4
Advertisement
FULLERTON, Calif., Feb. 8 Beckman Coulter, Inc.(NYSE: BEC), a leading developer, manufacturer and marketer of products thatsimplify, automate and innovate complex biomedical testing, announced todayfourth quarter and year ended December 31, 2007 results. For the fourthquarter, revenue was $789 million, rising on strong sales to clinicaldiagnostics customers partially offset by softness in demand for life scienceproducts. In constant currency, revenue increased 6.8%. Reported netearnings were $44.8 million, or $0.69 per fully diluted share.

See "Non-GAAP Financial Measures," where the impacts of certain items onreported results are discussed.

Total revenue from clinical diagnostics products increased 12.8% overprior year quarter, or 8.8% in constant currency. Within clinicaldiagnostics, revenue was driven by increases in Immunoassay of 19.2%,Chemistry of 12.8% and Cellular of 5.5%. Clinical Automation systems revenuegrew more than 75% over prior year quarter.

Markets for the company's life science products continued to be soft inmost geographies. Compared to fourth quarter 2006, sales of life scienceproducts grew 3.7%. In constant currency, life science product sales declined0.7%.

The company's consumables sales grew 10.9%, or 7% in constant currency.The fourth quarter 2006 acquisition of Lumigen, Inc. contributed about 1.0% tothis growth. Access immunoassay consumables grew 18.2%, or 14.4% in constantcurrency, over prior year quarter. Recurring revenue, comprised of supplies,test kits, service revenue and operating-type lease payments, increased 12.9%to $576 million and represented 73.0% of total revenue.

Compared to prior year quarter, revenue in the United States increased4.2%, with sales of clinical diagnostics products growing 7.4% partiallyoffset by a 10.6% decline in revenue from life science markets. In constantcurrency, international revenue increased 9.5%. International revenue fromclinical diagnostics products increased 10.4%, and life science product saleswere up 6.7% over prior year quarter.

Scott Garrett, president and chief executive officer, said, "Fourthquarter results demonstrate the ongoing strength of our clinical diagnosticsbusiness worldwide. We continue to gain market share in both ClinicalChemistry and Immunoassay. Sales of our Immunoassay systems grew at more thantwice the market rate with placements of the new mid-range Immunoassay system,the UniCel(R) DxI 600, contributing to this growth."

Gross profit margin was consistent with prior year quarter. Operatingincome was $74.6 million. Adjusted operating income was $114.2 million, or14.5% of revenue, excluding expenses for supply chain restructuring and thewrite off of in-process R&D associated with the acquisition of NexGenDiagnostics LLC, a spin out of Lumigen, Inc.

The tax rate for the quarter was approximately 30.3%. Net earnings were$44.8 million, or $0.69 per fully diluted share. Excluding the in-process R&Dwrite off and supply chain restructuring, adjusted net earnings were $69.6million and adjusted earnings per fully diluted share were $1.08.

Full Year 2007 Discussion

Revenue for full year 2007 was $2,761.3 million, up 9.2% over prior year,or 6.8% in constant currency. The 2006 acquisition of Lumigen contributed0.8% to this growth. Compared to prior year, Clinical Diagnostics revenuegrew 11.9%, while sales to life sciences markets declined 2%.

Consumables revenue grew 10.6%, or 8.3% in constant currency. The Lumigencontribution to consumables sales growth was 1.4%. Access Immunoassayconsumables grew 21.5% accelerating from 2006. Full year 2007 recurringrevenue was up 11.8% to $2,162.8 million, or 78.3% of total revenue.

Gross profit margin declined 40 basis points from prior year to 46.9%,driven primarily by a temporary increase in distribution costs largelyresu
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Roche Purchases Shares in Tender Offer for Ventana
S
Stereotaxis to Present at the Deutsche Bank Small-...